Remed Co.Ltd (302550) - Net Assets
Based on the latest financial reports, Remed Co.Ltd (302550) has net assets worth ₩39.46 Billion KRW (≈ $26.74 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩53.91 Billion ≈ $36.53 Million USD) and total liabilities (₩14.45 Billion ≈ $9.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Remed Co.Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩39.46 Billion |
| % of Total Assets | 73.2% |
| Annual Growth Rate | 32.38% |
| 5-Year Change | 51.22% |
| 10-Year Change | N/A |
| Growth Volatility | 59.74 |
Remed Co.Ltd - Net Assets Trend (2017–2025)
This chart illustrates how Remed Co.Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Remed Co.Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Remed Co.Ltd (2017–2025)
The table below shows the annual net assets of Remed Co.Ltd from 2017 to 2025. For live valuation and market cap data, see Remed Co.Ltd (302550) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩39.46 Billion ≈ $26.74 Million |
-1.95% |
| 2024-12-31 | ₩40.25 Billion ≈ $27.28 Million |
+30.70% |
| 2023-12-31 | ₩30.79 Billion ≈ $20.87 Million |
+2.93% |
| 2022-12-31 | ₩29.92 Billion ≈ $20.28 Million |
+14.64% |
| 2021-12-31 | ₩26.10 Billion ≈ $17.69 Million |
+5.29% |
| 2020-12-31 | ₩24.79 Billion ≈ $16.80 Million |
+0.66% |
| 2019-12-31 | ₩24.62 Billion ≈ $16.69 Million |
+124.98% |
| 2018-12-31 | ₩10.94 Billion ≈ $7.42 Million |
+161.50% |
| 2017-12-31 | ₩4.19 Billion ≈ $2.84 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Remed Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 373.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩9.93 Billion | 24.78% |
| Other Components | ₩30.14 Billion | 75.22% |
| Total Equity | ₩40.07 Billion | 100.00% |
Remed Co.Ltd Competitors by Market Cap
The table below lists competitors of Remed Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MGB Bhd
KLSE:7595
|
$64.62 Million |
|
Ardiden Ltd
AU:ADV
|
$64.63 Million |
|
TAPEX INC
KO:055490
|
$64.65 Million |
|
Asia File Corporation Bhd
KLSE:7129
|
$64.66 Million |
|
Formosa Prosonic Industries
KLSE:9172
|
$64.61 Million |
|
Quest For Growth - Pricaf
BR:QFG
|
$64.61 Million |
|
Evergreen Corp
NASDAQ:EVGR
|
$64.59 Million |
|
ad pepper media International N.V
XETRA:APM
|
$64.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Remed Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 40,248,542,040 to 40,066,322,970, a change of -182,219,070 (-0.5%).
- Net income of 526,195,000 contributed positively to equity growth.
- Share repurchases of 1,999,997,550 reduced equity.
- New share issuances of 5,000,000 increased equity.
- Other factors increased equity by 1,286,583,480.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩526.20 Million | +1.31% |
| Share Repurchases | ₩2.00 Billion | -4.99% |
| Share Issuances | ₩5.00 Million | +0.01% |
| Other Changes | ₩1.29 Billion | +3.21% |
| Total Change | ₩- | -0.45% |
Book Value vs Market Value Analysis
This analysis compares Remed Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.49x to 2.38x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩2066.27 | ₩3085.00 | x |
| 2018-12-31 | ₩2118.46 | ₩3085.00 | x |
| 2019-12-31 | ₩4228.73 | ₩3085.00 | x |
| 2020-12-31 | ₩4070.80 | ₩3085.00 | x |
| 2021-12-31 | ₩4259.03 | ₩3085.00 | x |
| 2022-12-31 | ₩4882.52 | ₩3085.00 | x |
| 2023-12-31 | ₩1006.13 | ₩3085.00 | x |
| 2024-12-31 | ₩1313.68 | ₩3085.00 | x |
| 2025-12-31 | ₩1296.34 | ₩3085.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Remed Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.15%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.35x
- Recent ROE (1.31%) is above the historical average (-2.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.87% | 0.58% | 0.50x | 3.01x | ₩-382.30 Million |
| 2018 | -67.44% | -92.21% | 0.37x | 1.97x | ₩-8.48 Billion |
| 2019 | 17.72% | 23.52% | 0.53x | 1.42x | ₩1.90 Billion |
| 2020 | -7.40% | -11.02% | 0.23x | 2.96x | ₩-4.31 Billion |
| 2021 | 2.88% | 3.73% | 0.26x | 2.96x | ₩-1.86 Billion |
| 2022 | 13.37% | 18.72% | 0.27x | 2.61x | ₩1.01 Billion |
| 2023 | 2.59% | 4.30% | 0.34x | 1.79x | ₩-2.29 Billion |
| 2024 | 17.82% | 28.07% | 0.43x | 1.47x | ₩3.15 Billion |
| 2025 | 1.31% | 2.15% | 0.45x | 1.35x | ₩-3.48 Billion |
Industry Comparison
This section compares Remed Co.Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $103,716,724,510
- Average return on equity (ROE) among peers: -3.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Remed Co.Ltd (302550) | ₩39.46 Billion | 0.87% | 0.37x | $64.62 Million |
| Shinhung (004080) | $77.28 Billion | 1.29% | 0.82x | $88.63 Million |
| HansBiomed Corporation (042520) | $33.89 Billion | -92.49% | 2.73x | $258.75 Million |
| JVM Co. Ltd (054950) | $104.90 Billion | 4.97% | 0.55x | $195.14 Million |
| Huvitz Co. Ltd (065510) | $78.68 Billion | 3.95% | 0.79x | $58.02 Million |
| Vieworks Co. Ltd (100120) | $126.17 Billion | 15.56% | 0.09x | $165.07 Million |
| Corentec Co Ltd (104540) | $60.18 Billion | 0.77% | 0.59x | $50.52 Million |
| Humasis Co. Ltd (205470) | $346.73 Billion | 52.67% | 0.35x | $61.42 Million |
| NH SPAC 2 (206640) | $151.09 Billion | 29.36% | 0.27x | $169.86 Million |
| Hana Must SPAC 2 (208370) | $26.92 Billion | -55.25% | 0.69x | $75.64 Million |
| DRTECH Corporation (214680) | $31.33 Billion | 3.98% | 0.59x | $98.45 Million |
About Remed Co.Ltd
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells,… Read more